Management of Multiple Myeloma in Older Patients

INTRODUCTION

Multiple myeloma is a haematological malignancy predominantly affecting older people and has a median age of onset of 70 years. Traditionally, the term ‘elderly’ in myeloma applied to those aged over 65–70 years, as these patients were considered as transplant-ineligible. However, this is a heterogeneous group of patients with varying degrees of fitness, physiological reserve to tolerate treatment, and life expectancy. In recent years, there have been renewed interests in this group of patients, with specifically designed prospective trials to determine treatment outcomes and tolerability, and research on the impact of frailty amongst these patients. This review aims to summarise key findings from the literature on older patients with myeloma, including frailty assessment, disease biology, and chemotherapy treatment in the frontline and relapsed settings.

METHODS

A literature search using the keywords “elderly”, “frailty”, “myeloma”, and “transplant-ineligible” was conducted in Google Scholar, PubMed, and Medline. Articles written in English were included and a preferential focus was placed on Phase III clinical trials and systematic reviews that were published within the last 10 years. Preliminary analyses, Phase I/II trials, post hoc analyses, and commentaries were included if they contained relevant merits.

FRAILTY ASSESSMENT

Frailty is a cumulative state of physiological decline associated with ageing. It has been reported that frail individuals have a reduced physiological reserve to external insult such as chemotherapy. One of the earlier definitions of frailty was described by Fried et al. as having three of the following five components: unintentional weight loss, poor grip strength,
self-reported exhaustion, slow mobility, and a low level of physical activity. Since then, several surrogate scoring tools have been developed for predicting frailty amongst patients with myeloma (Table 1).

The International Myeloma Working Group (IMWG) frailty assessment tool was developed based on a cohort of 869 transplant-ineligible (TI) patients with myeloma (Table 1). The frail score was composed of age categories, Katz Activity of Daily Living (ADL), Instrumental Activity of Daily Living (IADL), and Charlson Comorbidity Index (CCI). Three groups were identified: fit (score of 0), intermediate fit (score of 1), and frail (score of ≥2). This tool was predictive of 3-year overall survival (OS) (84% in fit; 76% in intermediate fit; and 57% in frail patients), serious treatment-related events, and incidence of treatment discontinuation. The Revised Myeloma Comorbidity Index (R-MCI) is an updated version of the Initial Myeloma Comorbidity Index, with additional information on adverse cytogenetics and frailty assessment (Table 1). The score was internally validated to predict median OS (10.1 years in the fit group; 4.4 years in the intermediate fit group; and 1.2 years in the frail group).

Table 1: Frailty assessment tools in multiple myeloma.

| Items measured                  | Frailty groups | Prognostication in myeloma in derivation cohort |
|--------------------------------|----------------|-----------------------------------------------|
| IMWG tool                      |                |                                               |
| 1. Age in years: ≤75 scores 0; 76–80 scores 1; >80 scores 2 | Fit (score of 0) | 3-year OS: 84% in fit; 76% in intermediate fit (HR=1.61; p=0.042); 57% in frail (HR: 3.57; p<0.001) |
| 2. ADL: >4 scores 0; ≤4 scores 1 | Intermediate fit (score of 1) | 3-year PFS: 48% in fit; 41% in intermediate fit (HR: 1.18; p=0.211); 33% in frail (HR: 1.68; p<0.001) |
| 3. IADL: >5 scores 0; ≤5 scores 1 | Frail (score ≥2) | Grade ≥3 non-haematological AE (intermediate fit HR: 1.13, p=0.462; frail HR: 1.57, p=0.008) |
| 4. CCI: ≤1 scores 0; ≥2 scores 1 |                |                                               |
| R-MCI                          |                |                                               |
| Renal function (eGFR<sub>MDRD</sub>): <60 scores 1 | 1. Fit (score ≤3) | Median OS: 10.1 years in fit; 4.4 years in intermediate fit; 1.2 years in frail |
| Moderate/severe lung disease (dyspnoea or lung function): scores 1 | 2. Intermediate fit (score of 4–6) | Median PFS: 4.1 years in fit; 1.9 years in intermediate fit; 0.9 years in frail |
| KPS: 80–90% scores 2; ≤70% scores 3 | 3. Frail (score) |                                               |
| Age in years: <60 scores 0; 60–69 scores 1; ≥70 scores 2 |                |                                               |
| Frailty defined by Fried: ≥2 factors scores 1 |                |                                               |
| Unfavourable cytogenetics: scores 1 |                |                                               |
| GAH scale                      |                |                                               |
| Polypharmacy: ≥5 medications scores 1 | Score ≤1 | Predictive of survival of patients with haematological malignancies (n=164) in a cohort of 363 patients. Amongst them, 60 patients had myeloma. |
| Gait speed over 4 metres: <0.8 m/sec scores 1 | Score 2–6 |                                               |
| Depressed mood: item from CES-D scores 1 | Score >6 |                                               |
| ADL: requires help in at least one area scores 1 |                |                                               |
| Subjective health status: poor or fair scores 1 |                |                                               |
| Nutrition: items score of ≤8 scores 1 in the scale |                |                                               |
| Mental status (SPMSQ): ≥3 errors scores 1 |                |                                               |
| Comorbidities index: ≥3 scores 1 |                |                                               |
It remained predictive of survival outcomes in the younger subgroup (age <65 years).

This emphasised that frailty was not limited to older patients.

These tools are not without shortfalls. The ADL and IADL assessments of the IMWG tool can take on average 15–20 minutes to complete, which affects its adoption in day-to-day clinical practice. Meanwhile, the score appeared to have limited ability to predict OS when applied to a separate cohort of patients aged ≥75 years. There was also inconsistency across different frailty tools, with the IMWG tool classifying more patients into the frail category than R-MCI and CCI.

Simplified tools have been proposed to address the time constraint issue in frailty assessment at a day-to-day clinical practice. The first group, including the Geriatric Assessment in Haematology (GAH) Scale and the Medicare Health Outcomes Survey (MHOS) Frailty Index, were based on self-reported elements (Table 1). The former was a 30-item list shown to predict mortality in haematology patients. The latter derived 25 questionnaire items on ADL, chronic health conditions, functional status, subjective general health, and mental health. Every 10% increase in the frailty index predicted a 16% increased risk of death (aHR: 1.16; p<0.001).

Another approach is to use performance-based assessment such as gait speed, which can be easily obtained using the 4 m gait speed test...
developed by the National Institutes of Health (NIH). In a recent analysis of patients aged ≥75 years with a haematological malignancy, reduced gait speed was associated with increased mortality, hospitalisation, and emergency visits. In a study of prognostication in patients with myeloma, performance status (PS) consistently contributed to survival outcomes regardless of their age groups. A simplified frailty score based on a patient’s age, CCI, and Eastern Cooperative Oncology Group (ECOG) PS was retrospectively analysed from the FIRST trial cohort and showed frail patients experienced worse PFS, OS, and more treatment-related adverse events. The performance of this score was validated in an independent dataset from the HOVON87/NMSG18 study with 636 TI patients. Similarly, in a post hoc analysis of the ASPIRE and ENDEAVOR trials, frailty score based on age, CCI, and PS appeared to show worse PFS and OS in frail individuals. Some studies explored the use of biomarkers in frailty assessment. For example, the UK Myeloma Research Alliance Risk Profile (UK-MRP) was based on the non-intensive arms of NCRI-Myeloma-XI and MRI-IX trials and found that World Health Organization (WHO) PS, International Staging System (ISS), age, and C-reactive protein were associated with progression-free survival (PFS), early mortality, and the percentage of treatment dose delivered (Table 1). Although these models appeared to show prognostic significance, some weighed more heavily towards disease characteristics. PS-based assessments are convenient for use in a day-to-day clinical setting; however, they may not encompass the full spectrum of the frailty phenotype and can be subjective.

Despite a lack of consensus on an ideal frailty assessment tool in a day-to-day clinical practice, the above data indicated that some form of frailty assessment would provide prognostic information on older patients with myeloma. Questions remain on tailoring treatment based on frailty; hopefully, data from the FRAIL-M study and the UK MRC-XIV study will provide further insight.

FRONTLINE THERAPY

Novel agents such as bortezomib and lenalidomide had been established as the standard of care. The addition of bortezomib to melphalan and prednisolone (VMP) for TI patients in the VISTA study showed survival benefit even in those aged ≥75 years (Table 2). A reduced once-weekly bortezomib dosing showed a reduction of neuropathic and gastrointestinal adverse effects without affecting efficacy. Meanwhile, continuous lenalidomide and dexamethasone (Rd) became an established regimen after demonstrating superior PFS and OS over the previous standard of care of a melphalan, prednisolone, and thalidomide regimen in the FIRST trial (Table 2). Addition of an alkylating agent to the Rd regimen did not show superiority in the EMN01 study unless the patient was classified as fit according to the IMWG tool.

Regimens combining immunomodulatory drugs (IMiD) and bortezomib were investigated for their synergistic effect. Bortezomib and thalidomide combination (VT) demonstrated a higher incidence of Grade ≥3 cardiac complications (8% versus 0% in the VMP group), offsetting the potential benefit. In the UPFRONT study, bortezomib, thalidomide, and dexamethasone (VTD) did not show superior OS to the VMP regimen but more neuropathy, whilst the doublet combination of bortezomib and dexamethasone had comparable efficacy (Table 2). Using lenalidomide with bortezomib appeared to be more favourable, with better tolerance than thalidomide. The combination of lenalidomide, bortezomib, and dexamethasone demonstrated superior survival outcome and duration of response than Rd alone in the SWOG-S0777 trial (Table 2). However, the study population was generally younger (median age of 63 years) than what was considered as ‘elderly’, and 10% proceeded for autologous transplant. Subgroup analysis from the SWOG-S0777 trial demonstrated significant overall survival benefit but not PFS benefit in those aged >75 years, whilst neurological toxicity was significantly more prevalent with bortezomib (33% versus 11% in Rd).
Table 2: Upfront chemotherapy treatment, dosage regimens, and efficacy in older patients with myeloma.

| Trial (year)     | Treatment dose regimens                                                                                                                                  | Efficacy                                                                                     |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| VISTA (2008)²⁰ | 6-weekly cycle, total of 9 cycles  
Bortezomib: 1.3 mg/m² IV Day 1, 4, 8, 11, 22, 25, 29, 32 (Cycle 1–4); Day 1, 8, 22, 29 (Cycle 5–9)  
Melphalan: 9 mg/m² Day 1–4  
Prednisolone: 60 mg/m² Day 1–4 | Median OS: 56.4 months versus 43.1 months in MP  
Median time to next treatment: 27 months versus 19.2 months in MP  
Median treatment-free interval: 16.6 months versus 8.3 months in MP |
| RVd-Lite (2014)²¹ | 35-day cycle  
Bortezomib: 1.3 mg/m² weekly subcutaneous Day 1, 8, 15, 22  
Lenalidomide: 15 mg Day 1–21  
Dexamethasone: 20 mg Day 1, 2, 8, 9, 15, 16, 22, 23 for <75 years of age; Day 1, 8, 15, 22 for age ≥75 years | Median PFS: 35.1 months  
Median OS: not reached after 30 months  
ORR: 91.4% |
| FIRST (2014)²²  | 28-day cycles, continuous or 18 cycles  
Lenalidomide: 25 mg Day 1–21  
Dexamethasone: 40 mg Day 1, 8, 15, 22  
42-day cycle, total of 12 cycles  
Melphalan: 0.25 mg/kg Day 1–4  
Prednisolone: 2 mg/kg Day 1–4  
Thalidomide: 200 mg daily | Median PFS: 26 months in Rd continuous; 21 months with Rd18; and 21.9 months with MPT  
Median OS: 59.1 months for Rd continuous; 62.3 months for Rd18; 49.1 months for MPT  
ORR: 81% in Rd continuous; 79% in Rd18; 67% in MPT |
| EMN01 (2014)²³  | 28-day cycle, total of 9 cycles of induction  
MPR  
Lenalidomide: 10 mg Day 1–21  
Melphalan: 0.18 mg/kg Day 1–4 for 65–75 years of age; 0.13 mg/kg for those >75 years  
Prednisolone: 1.5 mg/kg Day 1–4  
CPR  
Lenalidomide: 10 mg Day 1–21  
Cyclophosphamide: 50 mg alternating days for 28 days in ages 65–75 years; 21 days in ages >75 years  
Prednisolone: 25 mg alternating days  
Rd  
Lenalidomide: 25 mg Day 1–21  
Dexamethasone: 40 mg Day 1, 8, 15, 22 in ages 65–75 years; 20 mg in those aged >75 years  
Maintenance either lenalidomide 10 mg Day 1–21 or in combination with prednisolone 25 mg every other day | Median PFS: 24 months in MPR; 20 months in CPR; 21 months in Rd  
4-year OS: 65% in MPR; 68% with CPR; 58% with Rd  
ORR: 71% in MPR; 68% in CPR; 74% with Rd |
| Trial (year) | Treatment dose regimens | Efficacy |
|-------------|-------------------------|----------|
| **UPFRONT (2015)**<sup>24</sup> | 21-day cycle, total of 8 cycles  
VD  
Bortezomib: 1.5 mg/m<sup>2</sup> IV Day 1, 4, 8, 11  
Dexamethasone: 20 mg Day 1, 2, 4, 5, 8, 9, 11, 12 (Cycle 1–4); Day 1, 2, 4, 5 (cycle 5–8)  
VTD  
Thalidomide: 100 mg Day 1–21  
VMP  
Melphalan: 9 mg/m<sup>2</sup> Day 1–4  
Prednisolone: 60 mg/m<sup>2</sup> Day 1–4  
Maintenance with bortezomib IV 1.5 mg/m<sup>2</sup> Day 1, 8, 15, 22 | Median PFS: 14.7 months in VD; 15.4 months in VTD; 17.3 months in VMP (p=0.46)  
ORR over 13 cycles: 73% in VD; 80% in VTD; 70% in VMP  
Median OS: 49.8 months in VD; 51.5 months in VTD; 53.1 months in VMP (p=0.79) |
| **SWOG-S07777 (2017)**<sup>25</sup> | 21-day cycle, total of 8 cycles  
Bortezomib: 1.3 mg/m<sup>2</sup> IV Day 1, 4, 8, 11  
Lenalidomide: 25 mg Day 1–14 plus 20 mg Day 1, 2, 4, 5, 8, 9, 11, 12  
Dexamethasone: 40 mg Day 1, 8, 15, 22  
28-day cycle, total of 6 cycles  
Lenalidomide: 25 mg Day 1–21  
Dexamethasone: 40 mg Day 1, 8, 15, 22 | Median PFS: 43 months versus 30 months in Rd (HR: 0.712; p=0.0037)  
Median response duration: 52 months versus 38 months in Rd (HR=0.695; p=0.0133)  
Median OS: 75 months versus 64 months in Rd (HR: 0.709; p=0.0125) |
| **TOURMALINE-MM2 (2020)**<sup>26</sup> | 28-day cycle, total of 18 cycles  
Ixazomib: 4 mg or placebo on Day 1, 8, 15  
Lenalidomide: 25 mg Day 1–21 (10 mg for those with renal impairment)  
Dexamethasone: 40 mg Day 1, 8, 15 and 22 (20 mg if aged >75 years)  
After 18 cycles, dexamethasone was discontinued and treatment continued with ixazomib 3 mg and lenalidomide 10 mg | Median PFS: 35.3 months in IRd versus 21.8 months in Rd (HR: 0.83; p=0.073)  
ORR: 82.1% in IRd versus 79.7% in Rd (HR: 1.16; p=0.436).  
CR/sCR: 25.6% in IRd versus 14.1% in Rd (HR: 2.10; p<0.001) |
| **CLARION (2019)**<sup>27</sup> | 42-day cycle, total of 9 cycles  
Carfilzomib: IV Day 1, 2, 8, 9, 22, 23, 29, 30 at 20 mg/m<sup>2</sup> on Day 1, 2 of Cycle 1 and 36 mg/m<sup>2</sup> thereafter; OR  
bortezomib 1.3 mg/m<sup>2</sup> subcutaneous or IV on Day 1, 4, 8, 11, 22, 25, 29, 32 for cycle 1–4; Day 1, 8, 22, 29 for Cycle 5–9 AND  
Melphalan: 9 mg/m<sup>2</sup> Day 1–4  
Prednisolone: 60 mg/m<sup>2</sup> Day 1–4 | Median PFS: 22.3 months versus 22.1 months in VMP (p=0.1590)  
ORR: 84.3% versus 78.8% in VMP (p=0.02) |
| **AGMT-MM-02 (2020)**<sup>28</sup> | Carfilzomib: 20 mg/m<sup>2</sup> on Day 1, 2; 27 mg/m<sup>2</sup> on Day 8, 9, 15, 16 for Cycle 1; 27 mg/m<sup>2</sup> on Day 1, 2, 8, 9, 15, 16 for Cycle 2; 56 mg/m<sup>2</sup> on Day 1, 8, 15 for Cycle 3–9  
Dexamethasone: weekly (20 mg in patients aged ≥75 years)  
Lenalidomide: 25 mg Day 1–21 OR thalidomide 100 mg Day 1–28 (50 mg in patients aged ≥75 years)  
After 9 cycles of chemotherapy, randomised to either carfilzomib 56 mg/m<sup>2</sup> on Day 1 and Day 15 every 4 weeks or observation for 1 year | Interim analysis  
ORR: 96.6%  
PFS: 22.3 months  
24-month OS: 78.0% |
In another study, O’Donnell et al. demonstrated this regimen can be dose-reduced in older patients (bortezomib: 1.3 mg/m² subcutaneous weekly; lenalidomide: 15 mg on Day 1–21; and dexamethasone: 20 mg) and achieved comparable PFS of 35 months (Table 2). Only one patient from a cohort of 50 experienced Grade 3 peripheral neuropathy. These data support a bortezomib and lenalidomide combination as an efficacious upfront treatment option for fit, older patients with myeloma, which can be dose-adjusted to increase tolerability.

Carfilzomib was combined with melphalan and prednisolone in the CLARION study for the TI group against VMP. There were no significant differences between the two regimens in the median PFS, time to progression, response rate, median duration of response, and measurable residual disease (MRD) (Table 2). More patients in the regimen containing carfilzomib discontinued treatment because of adverse effects (16.7% versus 14.7%), while the VMP regimen had a high incidence of neuropathy (35.1% versus 2.5%; p<0.0001). The authors suggested once-weekly carfilzomib rather than twice weekly might increase its tolerability. A recent interim analysis from the AGMT-MM-02 study showed that older TI patients with myeloma who received twice weekly carfilzomib for two cycles followed by weekly carfilzomib at 56 mg/m² from Cycle 3 to 9 in combination with IMiDs and dexamethasone experienced high objective response rate (ORR; 96.6%), whilst, 47.1% of participants had achieved deep response as measured by negative MRD (Table 2).

DARatumumab, an anti-CD38 antibody, is emerging as a frontline treatment candidate. The addition of daratumumab to VMP showed higher response rates, higher incidence of negative MRD, prolonged PFS, and better OS in the ALCYONE study (Table 2). Meanwhile, the MAIA study investigated the addition of daratumumab to Rd in TI patients. It showed a superior event-free survival, ORR, and negative MRD status (Table 2). Both trials demonstrated higher infection rates in the daratumumab groups, especially respiratory infections. In a recent meta-analysis of upfront regimens for older TI patients with myeloma, daratumumab combinations appeared to be the most efficacious in prolonging PFS.

| Trial (year) | Treatment dose regimens | Efficacy |
|-------------|-------------------------|----------|
| ALCYONE (2018) | 42-day cycle, total of 9 cycles | 36-month OS: 78% versus 67.9% in VMP |
|             | Daratumumab: 16 mg/kg IV weekly in Cycle 1; every 3 weeks in Cycle 29; and every 4 weeks until stop | HR for death: 0.60 (p=0.0003) |
|             | Bortezomib: 1.3 mg/m² subcutaneously twice weekly on Week 1, 2, 4, 5 of Cycle 1 and once weekly on Week 1, 2, 4, 5 of Cycle 2–9 | HR for PFS: 0.42 (p=0.0001) |
|             | Melphalan: 9 mg/m² Day 1–4 | ORR: 90.9% versus 73.9% in VMP (p<0.0001) |
|             | Prednisolone: 60 mg/m² Day 1–4 |   |
| MAIA (2019) | 28-day cycle | Median PFS not reached versus 31.9 months in Rd |
|             | Daratumumab: 16 mg/kg IV weekly Cycle 1–2; every 2 weeks in Cycle 3–6; every 4 weeks after | HR for disease progression or death: 0.56 (p<0.001). |
|             | Lenalidomide: 25 mg Day 1–21 (10 mg in those with reduced creatine clearance) | ORR: 92.9% versus 81.3% in Rd (p<0.001) |
|             | Dexamethasone: 40 mg weekly |   |

CPR: cyclophosphamide, prednisolone, and thalidomide; CR/sCR: complete response/stringent complete response; HR: hazard ratio; IRd: ixazomib, lenalidomide, and dexamethasone; IV: intravenous; MP: melphalan and prednisolone; MPR: melphalan, prednisolone, and lenalidomide; MPT: melphalan, prednisolone, and thalidomide; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; Rd: lenalidomide and dexamethasone; Rd18: lenalidomide and dexamethasone for 18 cycles; VD: bortezomib and dexamethasone; VMP: bortezomib, melphalan, and prednisolone; VTD: bortezomib, thalidomide, and dexamethasone.
The aforementioned frailty assessment may help determine the optimal frontline chemotherapy regimen for older patients with myeloma. Fit patients appeared to benefit from lenalidomide triplet as opposed to Rd alone based on data from a post hoc analysis of the EMN01 trial. Although there was no head-to-head comparative trials, a pooled analysis by Larocca et al. compared bortezomib-based regimens against Rd (with maintenance lenalidomide). It showed no difference in survival outcomes for patients with standard-risk cytogenetics but improved outcomes for those with high-risk cytogenetics receiving VMP. Interestingly, those aged >75 years with standard cytogenetics appeared to gain benefit from the Rd-based regimen as opposed to the younger counterparts who benefited more from VMP.

Consideration of treatment toxicity profile can influence the choice of regimens. Continuous Rd in the FIRST trial showed a lower rate of neutropenia (30% versus 45% in melphalan, prednisolone, and thalidomide); however, a longer period of chemotherapy exposure might contribute to a higher rate of Grade 3 or 4 infections (32% versus 17% in melphalan, prednisolone, and thalidomide). Cardiac toxicity from the VTP regimen would limit its tolerability in older patients as they are more likely to have pre-existing cardiac comorbidities. Peripheral neuropathy and gastrointestinal toxicity from bortezomib can be less tolerated in older and frail patients. These issues continue to encourage studies of new chemotherapy regimens for older patients with myeloma.

Ixazomib is an oral proteasome inhibitor with the advantages of less hospital attendance for infusion and the potential for use as a maintenance treatment. The results from the Phase III TOURMALINE-MM02 study in TI patients with myeloma showed a median PFS of 35.3 months in the ixazomib, lenalidomide, and dexamethasone arm compared with 21.8 months in the Rd arm (hazard ratio: 0.83; p=0.073); however, the results failed to reach statistical significance (Table 2).

In a Phase II HOVON 143 study, a combination of ixazomib, daratumumab, and dexamethasone were studied in unfit and frail patients with myeloma who were classified according to the IMWG criteria. Interim efficacy analysis showed ORR of 87% and 78% in the unfit and frail groups, respectively. Elotuzumab, a monoclonal antibody against SLAMF7, in addition to Rd was recently studied in the ELOQUENT-1 trial. It did not show a significant difference in PFS against Rd. The use of belantamab mafodotin, an antibody-drug conjugate, was studied in the relapsed and refractory settings. The DREAMM-9 study is designed to specifically study its efficacy and safety in combination with bortezomib, lenalidomide, and dexamethasone in TI participants.

**QUALITY OF LIFE**

Despite the increasing use of novel agents and monoclonal antibodies in older patients with myeloma, it remains an incurable disease with poor survival outcomes. Measurement of the quality of life must be considered in this group. In the FIRST trial, continuous Rd improved health-related quality of life during the first 18 months, which might be maintained beyond this timeframe if treatment continued. In the HOVON-87/NMSG18 study, health-related quality of life was assessed using the EORTC QLQ-C30 and MY20 questionnaires at baseline, induction, and maintenance therapies. Improvement in the quality of life was evident in the lenalidomide-based treatment group during the maintenance phase as opposed to a higher incidence of neuropathy with thalidomide maintenance, which offset its potential benefit in reducing disease progression. In the CLARION study, quality of life measures appeared to favour carfilzomib, especially in the domains of physical function, fatigue, pain, and treatment side effects.

In the RVD-lite cohort, patients receiving a reduced-intensity triplet regimen experienced significant improvements in physical function, future perspective, and disease symptoms. Complications from skeletal and extramedullary diseases would impact on the quality of life in myeloma patients; therefore, radiation treatment, anti-resorptive therapies, and early access to palliative care would likely influence patient outcomes.
CYTOGENETICS IN TRANSPLANT-INELIGIBLE PATIENTS

It is recognised that older patients with myeloma have a different tumour genetic profile. The proportion of patients with t(4;14) and del(17p) appeared to lessen in the older age group, while the opposite was observed for those with gain(1q). Molecular study data showed that mutational signatures associated with hyperdiploidy were common with ageing. The impact of t(4;14) and gain(1q) were less in the very old group (>80 years), while del(17p) persistently predicted adverse outcomes across different age groups. The overall impact became smaller with advancing age. Poor PS and frailty predominated over adverse cytogenetic markers in prognosticating those >80 years. This illustrates that genetic markers are not uniform in their prognostic impact with advancing age.

Questions remain as to how best to tailor frontline treatment in TI patients based on the cytogenetic results in the absence of well-designed, risk-adapted studies. A recent post hoc analysis by Larocca et al. compared outcomes between bortezomib- and lenalidomide-based treatment arms from the GIMEMA-MM-03-05 and EMN01 trials based on the cytogenetic results. It showed that bortezomib could overcome cytogenetic adversity of t(4;14) and t(14;16) in TI patients to gain PFS benefit. This was not apparent in those with del(17p).

AUTOLOGOUS TRANSPLANT

Data on the role of autologous stem cell transplant in older patients with myeloma are not as robust because of the use of age threshold and PS as surrogate markers for transplant eligibility. The IFM-99-06 was a prospective study on autologous transplant in older patients. There was no significant survival benefit when comparing reduced-intensity conditioning autologous transplant with a melphalan plus prednisolone regimen. On the other hand, older patients with myeloma showed comparable benefits from autologous transplant to the younger patients.

Non-relapse mortality (NRM) was thought to be higher in patients over the age of 70 years with a conventional melphalan dose of 200 mg/m². Trials using a reduced-intensity regimen showed improved outcomes in older patients with myeloma without reducing their efficacy. This has been challenged by an analysis of the CIBMTR database, which included 15,999 patients with myeloma during 2013–2017. Age ≥70 years was not demonstrated to have significantly worse NRM (hazard ratio: 1.3; 99% confidence interval: 1.0–1.7). Furthermore, older patients who received reduced dose conditioning had worse outcomes than those receiving a full dose in aspects of Day-100 NRM, 2-year PFS, and 2-year OS.

A more comprehensive approach in selecting transplant candidates is needed than using biological age alone. A Haematopoietic Cell Transplantation Comorbidity Index (HCT-CI) ≥3 was not associated with a worse survival outcome. Using the IMWG classification tool, frailty was associated with cumulative gastrointestinal toxicity and infections. Overall, efficacy data appeared to support autologous transplant in fit and older patients with myeloma. With the emergence of efficacious and novel chemotherapy regimens, it is unclear whether this efficacy remains relevant in older patients with myeloma.

RELAPSED OR REFRACTORY TREATMENT

Outcomes in older patients with either relapsed or refractory myeloma remain poor, and there were few studies dedicated to this group. Data guiding current management in the relapsed or refractory settings were mostly based on subgroup analyses of clinical trials.

Newer IMiD such as pomalidomide showed efficacy in the relapsed or refractory settings. In the MMWP-164 study, Lee et al. investigated the efficacy of pomalidomide with cyclophosphamide and dexamethasone in older patients with myeloma. The outcome appeared decimal as only 10% of patients remained on treatment at the last follow-up, mostly because of disease progression. The median PFS was 6.9 months and an OS of 18.49 months was recorded. Guarded outcomes were
also observed in younger patients receiving pomalidomide after they experienced relapsed or refractory disease.\textsuperscript{55}

The ENDEAVOR trial showed that carfilzomib and dexamethasone were efficacious in the relapsed or refractory settings.\textsuperscript{56} In the subgroup analysis of the 17\% of patients aged ≥75 years, median PFS was 18.7 months in the carfilzomib group as opposed to 8.9 months in the bortezomib group.\textsuperscript{57} Median PFS in the younger subgroup receiving carfilzomib was 15.6 months, suggesting older patients might benefit more from carfilzomib.\textsuperscript{57} Carfilzomib was combined with lenalidomide and dexamethasone in the ASPIRE trial; however, no statistically significant difference in PFS was noted in the ≥65 age group when compared with Rd alone.\textsuperscript{58} This might be because of a higher discontinuation rate from cardiac toxicity in the carfilzomib group.

Despite recent studies focused on the use of ixazomib in the upfront setting, it was commonly used in the relapsed or refractory settings. In the TOURMALINE-MM1 study, ixazomib was added to the Rd backbone, demonstrating a superior medial PFS of 20.6 months as opposed to 14.7 months.\textsuperscript{59} However, the statistical difference has not been demonstrated in the older age group.

The potential role of isatuximab, an anti-CD38 monoclonal antibody, was supported by the ICARiA-MM study when it was used in conjunction with pomalidomide and dexamethasone.\textsuperscript{60} A significant proportion (65\%) of the participants who received the intervention were aged ≥65 years. Overall, this resulted in a median PFS of 11.53 months compared with 6.47 months in the control.\textsuperscript{60} There are reasonable data on daratumumab in the relapsed or refractory settings. The CASTOR study investigated the combination of daratumumab and bortezomib, showing potential benefits for those aged ≥65 years.\textsuperscript{61} When used with lenalidomide and dexamethasone, it was efficacious in those aged 65–74 years but not those aged ≥75 years.\textsuperscript{62} The CANDOR study investigated the combination of daratumumab and carfilzomib and found no PFS benefit in those aged >65 years, potentially because of its adverse effects.\textsuperscript{63} The emerging data on daratumumab in the upfront setting may phase out its use in the relapsed or refractory settings.

Elotuzumab used in conjunction with lenalidomide and dexamethasone was evaluated in the ELOQUENT-2 trial.\textsuperscript{64} Survival benefit had been shown in those aged ≥75 years. When used in conjunction with pomalidomide and dexamethasone, median PFS and OS were prolonged; however, this had not been observed in the older age group.\textsuperscript{55}

Although chimeric antigen receptor T cells have emerged as a novel immune therapy for heavily pre-treated patients with myeloma, this has not been studied in the older patients. It is worth noting that pre-treatment lymphodepleting agents, such as cyclophosphamide or fludarabine, and dose-related effects, including cytokine release syndrome and neurotoxicity, may limit its use in those with pre-existing age-related organ dysfunction, comorbidities, or frailty.

Despite novel agents, treatments in the relapsed or refractory settings for older patients with myeloma were mostly based on subgroup analyses in the large clinical trials. These were not necessarily representative of the real-world clinical scenarios of a significant proportion of older patients, who were likely to be frailer and less likely to tolerate salvage treatment.

CONCLUSION

Myeloma is a chronic disease of older people, with poor survival outcomes and quality of life. Older and frail patients are less able to tolerate treatment and more likely to experience disease progression. Although recent data on the novel chemotherapy agents showed promising results, it remains vital to consider frailty status, treatment toxicity, and quality of life when deciding on a management plan. In the authors’ review, several validated frailty assessment tools can predict survival outcomes. However, their use in a clinical setting requires an extensive amount of expertise and time. The authors recommend screening older patients with simplified or performance-based tools at the first instance and, if resources permit, conducting a detailed frailty assessment. Fit, older patients with myeloma should be offered highly efficacious treatment regimens and considered for autologous stem cell transplant. Frail, older patients with myeloma should be offered a balanced approach. Moreover, continuous oral therapy such as lenalidomide
may be favoured over parenteral proteasome inhibitors. Dose reduction should be considered if toxicity limits treatment tolerability as there is emerging evidence of highly efficacious dose-reduced regimens. Early palliative care involvement and supportive measures form important aspects in managing older patients with myeloma but they are outside the scope of this review.

References

1. Larocca A, Palumbo A. How I treat fragile myeloma patients. Blood. 2015;126(19):2179-85.

2. Kojima G et al. Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing. 2018;47(2):193-200.

3. Fried LP et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M46-56.

4. Palumbo A et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-74.

5. Engelhardt M et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910-21.

6. Dela Rubia J et al. GAH scale is a simple, comprehensive assessment tool in older patients with hematological malignancies that shows mortality prediction capacities. Clinical Lymphoma Myeloma and Leukemia. 2015;15(3):e99.

7. Mian HS et al. Development of a medicare health outcomes survey deficit-accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma. JCO clinical cancer informatics [Internet]. 2018;2:1-13.

8. Cook G et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019;6(3):e154-66.

9. Cook G et al. Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network. Leukemia. 2020;34(9):2285-94.

10. Murillo A et al. Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. J Geriatr Oncol. 2019;10(3):486-9.

11. Dold SM et al. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica. 2021;106(3):875-80.

12. Kallen M et al. NIH Toolbox Technical Manual. Available at: https://www.healthmeasures.net/images/nihtoolbox/Technical Manuals/MotorToolbox_4-Meter_Walk_Gait_Speed_Test_Technical Manual.pdf. Last accessed: 30 September 2020.

13. Liu MA et al. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019;134(4):374-82.

14. Pawlyn C et al. The relative importance of factors predicting outcome for myeloma patients at different ages. Results from 3894 patients in the Myeloma XI trial. Leukemia. 2020;34(2):604-12.

15. Facon T et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224-33.

16. Stege CAM et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia. 2020;34(7):1964-6.

17. Facon T et al. Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR. Journal of Clinical Oncology. 2019;37(15):8028.

18. Giri S et al. Simplified frailty assessment tools: are we really capturing frailty or something else? Leukemia. 2020;34(7):1967-9.

19. Cancer Research et al. Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FITNESS). NCT03720041. https://clinicaltrials.gov/ct2/show/ NCT03720041.

20. Miguel JFS et al. Continued overall survival benefit after 5 years’ follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial. Blood. 2011;118(21):476.

21. O’Donnell EK et al. Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (Rvd-lite) in transplant-ineligible multiple myeloma. Blood. 2019;134(Suppl 1):3178.

22. Benboubker L et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-17.

23. Magarotto V et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102-8.

24. Niesvizvy R et al. Community-based phase IIIB trial of three upfront bortezomib-based myeloma regimens. J Clin Oncol. 2015;33(3):3921-9.

25. Durie BGM et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519-27.

26. Facon T et al. The phase 3 TOURMALINE-MM2 trial: oral ixazomib, lenalidomide, and dexamethasone (IRd) vs placebo-Rd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Abstract 551. ASH Annual Meeting and Exposition, 5-8 December, 2020.

27. Facon T et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953-63.

28. Ludwig H et al. Carfilzomib-revlimid-dexamethasone vs carfilzomib-thalidomide-dexamethasone weekly (after 2 twice weekly cycles) followed by carfilzomib maintenance vs control in transplant non-eligible patients with newly diagnosed multiple myeloma (NDMM-interim efficacy analysis of combined data (AGMT MM-02). Blood. 2019;134(Suppl 1):696.

29. Mateos MV et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518-28.

30. Facon T et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-15.
31. Mateos MV et al. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leuk Lymphoma. 2020;61(3):680-90.

32. Facon T et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301-10.

33. Bringen S et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica. 2020;105(7):1937-47.

34. Mateos MV et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood. 2014;124(12):1887-93.

35. Mateos MV et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYON): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132-41.

36. Giri S et al. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: a systematic review and meta-analysis. J Geriatr Oncol. 2020;11(8):1091-9.

37. Larocca A et al. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. Haematologica. 2020;105(4):1074-80.

38. Stege CA et al. Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (Ixa Dara dex) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients: results of the interim efficacy analysis of the phase II HOVON 143 study. 2019;294846:EP929.

39. Bristol Myers Squibb. Bristol Myers Squib Reports Primary Results of ELOQUENT-1 Study Evaluating Emicizumab (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma. 2020. Available at: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-reports-primary-results-eloquent-1-study. Last accessed: 17 September 2020.

40. Lonial S et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2b study. Lancet Oncol. 2020;21(2):207-21.

41. Usmani SZ et al. DREAMM-9: phase III study of belantamab mafodotin plus VRD versus VRD alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM). Abstract PB203B. 14 May, 2020.

42. Vogl DT et al. Effect of treatment with lenalidomide plus low-dose dexamethasone until progression on health-related quality of life over time in transplant-ineligible patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17(1 Suppl):e87.

43. Nielsen LK et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica. 2020 Jun;105(6):1650-9.

44. Hoang PH et al. Multifunctional processes contributing to the development of multiple myeloma. Blood Cancer J. 2019;9(8):60.

45. Larocca A et al. Impact of bortezomib with lenalidomide-based induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma enrolled in the gimaena-MM03-03 and EMN01 trials. Blood. 2017;130(Suppl 1):744.

46. Facon T et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-18.

47. Marinì C et al. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Ann Hematol. 2019;98(2):369-79.

48. Garderet L et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Haematologica. 2016;101(11):1390-7.

49. Ghilardi G et al. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant. 2019;54(7):1029-37.

50. Munshi PN et al. Age no bar: A CIBMTR analysis of elderly newly diagnosed multiple myeloma patients with relapsed and refractory multiple myeloma. Bone Marrow Transplant. 2020;54(12):2088-95.

51. Dimopoulos MA et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497-503.

52. Lee HS et al. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KKMWP-16 study). Am J Hematol. 2020;95(4):413-21.

53. Garderet L et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018;132(24):2555-63.

54. Dimopoulos MA et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38.

55. Palumbo A et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Blood. 2015;126(23):1844.

56. Dimopoulos MA et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017;177(3):404-13.

57. Moreau P et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621-34.

58. Attal M et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-107.

59. Palumbo A et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-66.

60. Bahlis NJ et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875-84.

61. Dimopoulos M et al. Carfilzomib, dexamethasone, and daratumumab...
versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186-97.

64. Lonial S et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621-31.
65. Dimopoulos MA et al. Elotuzumab, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma: Efficacy after additional follow-up of the ELOQUENT-3 study. Clin Lymphoma Myeloma Leuk. 2019;19(10):e164-5.